Shares of Moderna Inc fell nearly 10% after the U.S. Patent Trial and Appeal Board determined that the company’s claims against Arbutus Biopharma’s vaccine technology patent were not valid.
Arbutus shares soared 56% after the patent board posted its opinion on its electronic docket.
Market Data 
Markets 
AI
